WPD’s drug candidate was found to be potentially capable of immune reprogramming in Glioblastoma animal models.
WPD Pharmaceuticals (CSE:WBIO) has announced that its drug candidate was the subject of a scientific paper published in 2019 which found that it is potentially capable of immune reprogramming in Glioblastoma animal models.
As quoted in the press release:
Currently in clinical trials at the University of Texas, MD Anderson Cancer Center, WP1066 represents a new class of drugs, which WPD identifies as “Immune/Transcription Modulators”. WP1066 and related analogs have not only demonstrated the ability to directly induce apoptosis (tumor cell death) but also the ability to stimulate an immune response to tumors allowing T-cells to attack tumor cells. These unique drug properties are a result of WP1066’s ability to inhibit the activated form of STAT3, (p-STAT3.